Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS other · 2025-09-25

Clinical Trial Update: Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study of Adebrelimab in combination with Apatinib for advanced hepatocellular carcinoma after prior systemic therapy is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adebrelimab (adebrelimab)
  • Apatinib (apatinib)

Snippet

Sponsor: Song Peng | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: NOT_YET_RECRUITING